This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KD020

Kadmon Holdings, Inc.

Drug Names(s): KD020

Description: KD020 is a reversible tyrosine kinase inhibitor targeting EGFR, HER2, VEGFR 2/3 and Src.

Kadmon is developing a related drug, KD019, derived from the same drug substance.


KD020 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug